Anavex Life Sciences Corp.(www.anavex.com) is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases.
Anavex is currently in a Phase 2a trial for Alzheimer's disease (AD) with lead therapeutic, ANAVEX 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the Sigma-1 Receptor. PART A topline data of our ongoing Phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. ANAVEX 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: Rett syndrome, as well is in epilepsy and multiple sclerosis (MS). In 2015, the Company was awarded a research by the Michael J. Fox Foundation (MJFF) to study ANAVEX 2-73 for the treatment of Parkinson’s disease.
Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.
Anavex is currently in a Phase 2a trial for Alzheimer's disease (AD) with lead therapeutic, ANAVEX 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the Sigma-1 Receptor. PART A topline data of our ongoing Phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. ANAVEX 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: Rett syndrome, as well is in epilepsy and multiple sclerosis (MS). In 2015, the Company was awarded a research by the Michael J. Fox Foundation (MJFF) to study ANAVEX 2-73 for the treatment of Parkinson’s disease.
Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.
Location: United States, New York
Employees: 11-50
Phone: +1 844-689-3939
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | SymBiosis | symbiosis.... |
Mentions in press and media 16
| Date | Title | Description |
| 14.01.2025 | Christopher Missling, PhD: Leading the Fight Against Neurodegenerative Diseases with Anavex Life Sciences | Share Tweet Share Share Email Learn more about Christopher Missling, PhD, on LinkedIn and explore the innovative work of Anavex Life Sciences at their website. In the relentless pursuit of solutions for neurodegenerative diseases like Alzhe... |
| 08.05.2024 | BERGER MONTAGUE PC ANNOUNCES THE FILING OF A CLASS ACTION COMPLAINT TO RECOVER LOSSES FOR INVESTORS WHO PURCHASED ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) | PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Berger Montague PC has filed a class action lawsuit on behalf of investors who purchased securities of Anavex Life Sciences Corporation ("Anavex" or the "Company") (NASDAQ: AVXL)... |
| 13.03.2024 | AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead the Anavex Class Action Lawsuit | - |
| 04.03.2024 | Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm | BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in their Anavex Life Sciences Corp. investment ... |
| 29.06.2023 | Roundups: 22 Recent Strategic Digital Health Partnerships | Advantus Health Partners forms a new 10-year, $2.9B strategic partnership with Medline to establish agility and scale, supply chain resiliency and enhanced clinical integration with the nurses and physicians who use Medline’s product. This ... |
| 21.07.2022 | 180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering | PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously-announced registered di... |
| 18.07.2022 | 180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering | PALO ALTO, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with ... |
| 02.02.2022 | A win in Rett syndrome? Not so fast — biotech shares slide amid concerns of last-minute trial changes | Normally, an announcement that a Phase III trial met all primary and secondary efficacy and safety endpoints is sure to get a biotech’s shares up. But Anavex found itself in an opposite situation Tuesday after declari... |
| 12.08.2021 | Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results | Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (bl... |
| 29.07.2021 | Anavex Life Sciences : Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer's D... | Pre-Treatment with ANAVEX®2-73 entirely prevented Abeta-induced cognitive decline Anavex planning a Phase 3 prevention trial of ANAVEX®2-73 including participants at risk for cognitive and functional decline related to Alzheimer's disease N... |
Show more